| 1 | Liver Cirrhosis, Experimental | 24.6% |
| 2 | Arthritis, Experimental | 24.6% |
| 3 | Hamartoma | 20.5% |
| 4 | Neoplasms, Hormone-Dependent | 20.5% |
| 5 | Neoplasms, Multiple Primary | 20.5% |
| 6 | Paraneoplastic Syndromes | 20.5% |
| 7 | Precancerous Conditions | 20.5% |
| 8 | Neoplasms, Second Primary | 20.5% |
| 9 | Medulloblastoma | 20.5% |
| 10 | Diabetes Mellitus, Experimental | 19.6% |
| 11 | Neoplasms, Neuroepithelial | 19.2% |
| 12 | Gliomatosis cerebri | 19.2% |
| 13 | Dermoid Cyst | 18.6% |
| 14 | melanoma | 18.4% |
| 15 | Adenoma, Acidophil | 17.6% |
| 16 | Ganglioneuroma | 17.6% |
| 17 | Glioma | 17.6% |
| 18 | Malignant Glioma | 17.6% |
| 19 | Neuroectodermal Tumors | 17.5% |
| 20 | Carcinoid Tumor | 17.2% |
| 21 | Multiple Endocrine Neoplasia | 17.2% |
| 22 | Neurilemmoma | 17.2% |
| 23 | Hutchinson's Melanotic Freckle | 17.2% |
| 24 | Melanoma, Amelanotic | 17.2% |
| 25 | Astrocytoma | 16.8% |
| 26 | Ependymoma | 16.8% |
| 27 | oligodendroglioma | 16.8% |
| 28 | Ganglioglioma | 16.8% |
| 29 | gliosarcoma | 16.8% |
| 30 | Anaplastic astrocytoma | 16.8% |
| 31 | Anaplastic Oligodendroglioma | 16.8% |
| 32 | Malignant Carcinoid Syndrome | 16.6% |
| 33 | Carcinosarcoma | 16.5% |
| 34 | Hemangiosarcoma | 16.5% |
| 35 | lymphangiosarcoma | 16.5% |
| 36 | Acanthoma | 16.5% |
| 37 | Glioblastoma | 16.4% |
| 38 | Neuroblastoma | 16.4% |
| 39 | Glioblastoma Multiforme | 16.4% |
| 40 | Ganglioneuroblastoma | 16.2% |
| 41 | Meningioma | 16.1% |
| 42 | Paraneoplastic Encephalomyelitis | 15.7% |
| 43 | Basal cell carcinoma | 15.5% |
| 44 | Carcinoma, Papillary | 15.5% |
| 45 | Squamous cell carcinoma | 15.5% |
| 46 | Chondrosarcoma | 15.5% |
| 47 | Craniopharyngioma | 15.5% |
| 48 | Cystadenoma | 15.5% |
| 49 | leiomyosarcoma | 15.5% |
| 50 | liposarcoma | 15.5% |
| 51 | Mesothelioma | 15.5% |
| 52 | synovial sarcoma | 15.5% |
| 53 | Neuroectodermal Tumor, Melanotic | 15.5% |
| 54 | Angiomyolipoma | 15.5% |
| 55 | Clear Cell Sarcoma of Soft Tissue | 15.5% |
| 56 | Alveolar Soft Part Sarcoma | 15.5% |
| 57 | Neuroendocrine Tumors | 15.5% |
| 58 | Sarcoma, Myeloid | 15.5% |
| 59 | Carcinoma, Basal Cell | 15.5% |
| 60 | Choriocarcinoma | 15.5% |
| 61 | Trophoblastic Neoplasms | 15.5% |
| 62 | Carcinoma, Lobular | 15.5% |
| 63 | Cyst | 15.1% |
| 64 | Neoplastic Processes | 15.1% |
| 65 | Neoplastic Syndromes, Hereditary | 15.1% |
| 66 | Pregnancy Complications, Neoplastic | 15.1% |
| 67 | Cystadenocarcinoma | 15% |
| 68 | Fibrosarcoma | 15% |
| 69 | Osteosarcoma | 15% |
| 70 | Mucoepidermoid Carcinoma | 15% |
| 71 | Adenofibroma | 14.8% |
| 72 | Fibroadenoma | 14.8% |
| 73 | Malignant Fibrous Histiocytoma | 14.8% |
| 74 | Abdominal Neoplasms | 14.6% |
| 75 | Erythroplasia | 14.6% |
| 76 | Follicular cyst | 14.6% |
| 77 | Head and Neck Neoplasms | 14.6% |
| 78 | leukemia | 14.6% |
| 79 | Mucocele | 14.6% |
| 80 | Neoplasms, Germ Cell and Embryonal | 14.6% |
| 81 | Neoplasms, Glandular and Epithelial | 14.6% |
| 82 | Pilonidal Cyst | 14.6% |
| 83 | Soft Tissue Neoplasms | 14.6% |
| 84 | Thoracic Neoplasms | 14.6% |
| 85 | Thyroglossal Cyst | 14.6% |
| 86 | Synovial Cyst | 14.6% |
| 87 | Germ Cell Cancer | 14.6% |
| 88 | Aberrant Crypt Foci | 14.6% |
| 89 | Bowen's Disease | 14.5% |
| 90 | Paraganglioma | 14.5% |
| 91 | Rhabdomyosarcoma | 14.5% |
| 92 | Giant Cell Tumor of Bone | 14.5% |
| 93 | Dermatofibrosarcoma | 14.3% |
| 94 | Dermatofibrosarcoma Protuberans | 14.3% |
| 95 | Multiple Endocrine Neoplasia Type 1 | 14.1% |
| 96 | Pheochromocytoma | 14% |
| 97 | Alveolar rhabdomyosarcoma | 14% |
| 98 | Carcinoid Heart Disease | 13.7% |
| 99 | Radiation Injuries, Experimental | 13.6% |
| 100 | Retinoblastoma | 13.1% |
| 101 | Thymoma | 13.1% |
| 102 | Leukemia, Plasma Cell | 13% |
| 103 | Carcinoma, Pancreatic Ductal | 12.9% |
| 104 | Leukemia, Radiation-Induced | 12.9% |
| 105 | Device Failure | 12.8% |
| 106 | Acoustic Neuroma | 12.8% |
| 107 | Melanoma, Experimental | 12.3% |
| 108 | Vipoma | 12.2% |
| 109 | Carcinoma 256, Walker | 12.1% |
| 110 | Neurofibrosarcoma | 11.9% |
| 111 | Adenoma | 11.9% |
| 112 | Ameloblastoma | 11.9% |
| 113 | Angiokeratoma | 11.9% |
| 114 | Carcinoma | 11.9% |
| 115 | Chordoma | 11.9% |
| 116 | Hemangioma | 11.9% |
| 117 | hemangiopericytoma | 11.9% |
| 118 | Lymphangioma | 11.9% |
| 119 | Mesenchymoma | 11.9% |
| 120 | Nevus | 11.9% |
| 121 | Retroperitoneal Neoplasms | 11.9% |
| 122 | Teratoma | 11.9% |
| 123 | Hepatoblastoma | 11.9% |
| 124 | Mixed Tumor, Mullerian | 11.9% |
| 125 | Germinoma | 11.9% |
| 126 | Teratocarcinoma | 11.9% |
| 127 | Angiofibroma | 11.9% |
| 128 | Sarcoma | 11.9% |
| 129 | Epithelioma | 11.9% |
| 130 | Neuritis, Autoimmune, Experimental | 11.9% |
| 131 | Hydatidiform Mole | 11.8% |
| 132 | Parathyroid Neoplasms | 11.8% |
| 133 | Peritoneal Neoplasms | 11.8% |
| 134 | Thyroid Neoplasm | 11.8% |
| 135 | Thyroid carcinoma | 11.8% |
| 136 | Neoplasms, Radiation-Induced | 11.7% |
| 137 | Lymphomatoid Granulomatosis | 11.6% |
| 138 | Basal Cell Nevus Syndrome | 11.4% |
| 139 | Optic Nerve Glioma | 11.4% |
| 140 | Composite Lymphoma | 11.4% |
| 141 | Digestive System Neoplasms | 11.3% |
| 142 | Endocrine Gland Neoplasms | 11.3% |
| 143 | Eye Neoplasms | 11.3% |
| 144 | Nervous System Neoplasms | 11.3% |
| 145 | Tuberous Sclerosis | 11.3% |
| 146 | Tracheal Neoplasms | 11.1% |
| 147 | Bone neoplasms | 10.9% |
| 148 | Electrophoresis | 10.9% |
| 149 | Leukoplakia | 10.9% |
| 150 | Lymphocele | 10.9% |
| 151 | Pancreatic Cyst | 10.9% |
| 152 | Skin Neoplasms | 10.9% |
| 153 | Hematologic Neoplasms | 10.9% |
| 154 | Leukoplakia, Oral | 10.9% |
| 155 | Paraneoplastic Cerebellar Degeneration | 10.8% |
| 156 | Barrett Esophagus | 10.7% |
| 157 | Breast Cyst | 10.7% |
| 158 | Histiocytic Disorders, Malignant | 10.7% |
| 159 | Actinic keratosis | 10.7% |
| 160 | Mediastinal Cyst | 10.7% |
| 161 | Neoplasm Invasiveness | 10.7% |
| 162 | Neoplasm Metastasis | 10.7% |
| 163 | Neoplasm Recurrence, Local | 10.7% |
| 164 | Parovarian Cyst | 10.7% |
| 165 | Pericardial Cyst | 10.7% |
| 166 | Splenic Neoplasms | 10.7% |
| 167 | Thymic Cyst | 10.7% |
| 168 | Carcinogenesis | 10.7% |
| 169 | Myxoid cyst | 10.7% |
| 170 | Metastasis | 10.7% |
| 171 | Adenocarcinoma | 10.6% |
| 172 | Carcinoma in Situ | 10.6% |
| 173 | Carcinoma, Transitional Cell | 10.6% |
| 174 | Phyllodes Tumor | 10.6% |
| 175 | Dysgerminoma | 10.6% |
| 176 | Hemangioendothelioma | 10.6% |
| 177 | Lipoma | 10.6% |
| 178 | Myoma | 10.6% |
| 179 | Myxoma | 10.6% |
| 180 | Neuroma | 10.6% |
| 181 | Papilloma | 10.6% |
| 182 | Pseudomyxoma Peritonei | 10.6% |
| 183 | Seminoma | 10.6% |
| 184 | Papillomatosis | 10.6% |
| 185 | Angiolipoma | 10.6% |
| 186 | Myelolipoma | 10.6% |
| 187 | Neoplasms, Bone Tissue | 10.6% |
| 188 | Neoplasms, Fibrous Tissue | 10.6% |
| 189 | Smooth Muscle Tumor | 10.6% |
| 190 | Adenomatosis, Pulmonary | 10.6% |
| 191 | Adenomatous Polyps | 10.6% |
| 192 | Carcinoma, Large Cell | 10.6% |
| 193 | Carcinoma, Small Cell | 10.6% |
| 194 | Desmoplastic Small Round Cell Tumor | 10.6% |
| 195 | Chondroma | 10.6% |
| 196 | Enchondroma | 10.6% |
| 197 | insulinoma | 10.6% |
| 198 | Gastrinoma | 10.4% |
| 199 | Glucagonoma | 10.4% |
| 200 | Endometrial Stromal Sarcoma | 10.3% |
| 201 | Thyroid Nodule | 10.2% |
| 202 | Hepatocellular Adenoma | 10.2% |
| 203 | Nephroblastoma | 10.2% |
| 204 | Lymphangioleiomyomatosis | 10.1% |
| 205 | Pancreatic Neoplasm | 10.1% |
| 206 | Adenoid Cystic Carcinoma | 9.9% |
| 207 | fibroma | 9.9% |
| 208 | Fibromatosis | 9.9% |
| 209 | Osteoblastoma | 9.9% |
| 210 | Osteoma | 9.9% |
| 211 | Rhabdomyoma | 9.9% |
| 212 | Chondromatosis | 9.9% |
| 213 | Adenocarcinoma, Clear Cell | 9.9% |
| 214 | Cholangiocarcinoma | 9.9% |
| 215 | Cervical Intraepithelial Neoplasia | 9.9% |
| 216 | Hemangioblastoma | 9.9% |
| 217 | Lymphoma, Extranodal NK-T-Cell | 9.9% |
| 218 | Intubation | 9.8% |
| 219 | Fibromatosis, Aggressive | 9.6% |
| 220 | Fibromatosis, Abdominal | 9.6% |
| 221 | Klatskin Tumor | 9.6% |
| 222 | Cytogenetic Analysis | 9.4% |
| 223 | Esophageal Neoplasms | 9.3% |
| 224 | Leydig Cell Tumor | 9.2% |
| 225 | Limbic Encephalitis | 9.2% |
| 226 | Mouth Neoplasms | 8.9% |
| 227 | Central Nervous System Neoplasms | 8.9% |
| 228 | Vascular Neoplasms | 8.9% |
| 229 | Thymus Neoplasms | 8.9% |
| 230 | Myasthenia Gravis, Autoimmune, Experimental | 8.8% |
| 231 | Genital Neoplasms, Female | 8.8% |
| 232 | Pancreatic Pseudocyst | 8.8% |
| 233 | Plasmacytoma | 8.8% |
| 234 | Malignant histiocytosis | 8.7% |
| 235 | Lymphatic Metastasis | 8.7% |
| 236 | Neoplasms, Unknown Primary | 8.7% |
| 237 | Leukemic Infiltration | 8.7% |
| 238 | Breast Neoplasms, Male | 8.7% |
| 239 | Histiocytic sarcoma | 8.7% |
| 240 | Neoplasm Micrometastasis | 8.7% |
| 241 | Triple Negative Breast Neoplasms | 8.7% |
| 242 | Prolactinoma | 8.7% |
| 243 | Growth Hormone-Secreting Pituitary Adenoma | 8.7% |
| 244 | Adenomatous Polyposis Coli | 8.7% |
| 245 | Lymphoma | 8.5% |
| 246 | Corpus Luteum Cyst | 8.4% |
| 247 | Ovarian Cysts | 8.4% |
| 248 | Lambert-Eaton Myasthenic Syndrome | 8.2% |
| 249 | Testicular Neoplasms | 8.2% |
| 250 | Adrenocortical carcinoma | 8.1% |
| 251 | Carcinoma, Ehrlich Tumor | 8% |
| 252 | Carcinoma, Lewis Lung | 8% |
| 253 | Leukemia L1210 | 7.8% |
| 254 | Leukemia P388 | 7.8% |
| 255 | Meningeal Neoplasms | 7.8% |
| 256 | Leukemia, Myelomonocytic, Chronic | 7.8% |
| 257 | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 7.8% |
| 258 | Mesoblastic Nephroma | 7.7% |
| 259 | granulosa cell tumor | 7.5% |
| 260 | Carcinoma, Ovarian Epithelial | 7.5% |
| 261 | Mastocytoma | 7.4% |
| 262 | Sarcoma 180 | 7.4% |
| 263 | Palatal Neoplasms | 7.4% |
| 264 | Gastric Lavage | 7.3% |
| 265 | Peritoneal lavage | 7.3% |
| 266 | Bronchoalveolar Lavage | 7.3% |
| 267 | Autopsy | 7.3% |
| 268 | Meningeal Carcinomatosis | 7.3% |
| 269 | Mastocytosis, Systemic | 7.3% |
| 270 | Leukemia, Myeloid, Chronic-Phase | 7.3% |
| 271 | Microscopy | 7.2% |
| 272 | Opsoclonus-Myoclonus Syndrome | 7.2% |
| 273 | Adrenal Gland Neoplasms | 7.1% |
| 274 | Gastrointestinal Neoplasms | 7.1% |
| 275 | Genital Neoplasms, Male | 7.1% |
| 276 | Liver neoplasms | 7.1% |
| 277 | Uveal Neoplasms | 7.1% |
| 278 | Choledochal Cyst | 7.1% |
| 279 | Urologic Neoplasms | 7% |
| 280 | Renal Cell Carcinoma | 7% |
| 281 | Papillary Renal Cell Carcinoma | 7% |
| 282 | Leukemia, Experimental | 7% |
| 283 | Mammary Neoplasms, Experimental | 7% |
| 284 | Nose Neoplasms | 6.9% |
| 285 | Sebaceous Gland Neoplasms | 6.9% |
| 286 | Spinal Neoplasms | 6.9% |
| 287 | Bone Marrow Neoplasms | 6.9% |
| 288 | Carcinoma, Endometrioid | 6.9% |
| 289 | Peutz-Jeghers Syndrome | 6.9% |
| 290 | Hodgkin Disease | 6.8% |
| 291 | Lymphoma, Non-Hodgkin | 6.8% |
| 292 | Polycystic Ovary Syndrome | 6.8% |
| 293 | Ear Neoplasms | 6.4% |
| 294 | Eyelid Neoplasms | 6.4% |
| 295 | Lung Neoplasms | 6.4% |
| 296 | Pleural Neoplasms | 6.4% |
| 297 | Myelitis, Transverse | 6.4% |
| 298 | Denys-Drash Syndrome | 6.3% |
| 299 | Nasopharyngeal carcinoma | 6.3% |
| 300 | Mastocytosis | 6.3% |
| 301 | Sturge-Weber Syndrome | 6.3% |
| 302 | Sarcoma, Experimental | 6.2% |
| 303 | Cell Transformation, Viral | 6.2% |
| 304 | Brain Neoplasms | 6.2% |
| 305 | Salivary Gland Neoplasms | 6.2% |
| 306 | Spinal Cord Neoplasms | 6.2% |
| 307 | Tongue Neoplasms | 6.2% |
| 308 | Gastrointestinal Stromal Tumors | 6.2% |
| 309 | Hemangioma, Cavernous | 6.2% |
| 310 | Leukemia, T-Cell | 6.1% |
| 311 | Uterine Neoplasms | 6.1% |
| 312 | Vaginal Neoplasms | 6.1% |
| 313 | Vulvar Neoplasms | 6.1% |
| 314 | Uterine Cancer | 6.1% |
| 315 | Leukemia, B-Cell | 6.1% |
| 316 | Fallopian Tube Neoplasms | 6.1% |
| 317 | neurofibroma | 6.1% |
| 318 | Lymphoma, Follicular | 6.1% |
| 319 | T-Cell Lymphoma | 6.1% |
| 320 | Mantle cell lymphoma | 6.1% |
| 321 | Pituitary Adenoma | 6.1% |
| 322 | Pituitary Neoplasms | 6.1% |
| 323 | Bronchial Neoplasms | 5.9% |
| 324 | Multiple Pulmonary Nodules | 5.8% |
| 325 | Supratentorial Neoplasms | 5.8% |
| 326 | Dupuytren Contracture | 5.7% |
| 327 | Endometrial Neoplasms | 5.7% |
| 328 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5.7% |
| 329 | Leukemia, Large Granular Lymphocytic | 5.7% |
| 330 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5.7% |
| 331 | Primary amyloidosis | 5.7% |
| 332 | Lymphoma, T-Cell, Cutaneous | 5.7% |
| 333 | Lymphoma, AIDS-Related | 5.7% |
| 334 | Enteropathy-Associated T-Cell Lymphoma | 5.7% |
| 335 | Primary Effusion Lymphoma | 5.7% |
| 336 | Urticaria Pigmentosa | 5.6% |
| 337 | Brain Stem Neoplasms | 5.5% |
| 338 | Mycosis Fungoides | 5.5% |
| 339 | Lymphomatoid Papulosis | 5.5% |
| 340 | Plasmablastic lymphoma | 5.5% |
| 341 | Choroid Plexus Papilloma | 5.4% |
| 342 | Prosthesis Failure | 5.4% |
| 343 | Pharyngeal Neoplasms | 5.3% |
| 344 | Immunosuppression | 5.3% |
| 345 | Central Nervous System Cysts | 5.2% |
| 346 | Bile Duct Neoplasms | 5.1% |
| 347 | gallbladder neoplasm | 5.1% |
| 348 | Intestinal Neoplasms | 5.1% |
| 349 | Penile Neoplasms | 5.1% |
| 350 | Prostatic Neoplasms | 5.1% |
| 351 | Stomach Neoplasms | 5.1% |
| 352 | Polycythemia Vera | 5.1% |
| 353 | ovarian neoplasm | 4.9% |
| 354 | Hypopharyngeal Neoplasms | 4.8% |
| 355 | Pleural Effusion, Malignant | 4.8% |
| 356 | Hypopharyngeal Cancer | 4.8% |
| 357 | Parotid Neoplasms | 4.8% |
| 358 | Polymerase Chain Reaction | 4.8% |
| 359 | Prostatic Neoplasms, Castration-Resistant | 4.8% |
| 360 | Nelson Syndrome | 4.7% |
| 361 | Glasgow coma scale | 4.7% |
| 362 | Tonsillar Neoplasms | 4.6% |
| 363 | Cerebellar Neoplasms | 4.6% |
| 364 | Laryngeal neoplasm | 4.6% |
| 365 | Liver Neoplasms, Experimental | 4.4% |
| 366 | Bladder Neoplasm | 4.3% |
| 367 | Kidney Neoplasm | 4.3% |
| 368 | Ureteral Neoplasms | 4.3% |
| 369 | Urethral Neoplasms | 4.3% |
| 370 | Waldenstrom Macroglobulinemia | 4.2% |
| 371 | Multiple Myeloma | 4.2% |
| 372 | Biopsy | 4.2% |
| 373 | Xeroderma Pigmentosum | 4.1% |
| 374 | Tuberculin Test | 4.1% |
| 375 | Cecal Neoplasms | 4.1% |
| 376 | Duodenal Neoplasms | 4.1% |
| 377 | Burkitt Lymphoma | 4% |
| 378 | Sezary Syndrome | 3.9% |
| 379 | Radicular Cyst | 3.9% |
| 380 | Appendiceal Neoplasms | 3.9% |
| 381 | Colonic Neoplasms | 3.9% |
| 382 | Rectal Neoplasms | 3.9% |
| 383 | Zollinger-Ellison syndrome | 3.8% |
| 384 | Amniocentesis | 3.7% |
| 385 | Nasopharyngeal Neoplasms | 3.6% |
| 386 | Colorectal Neoplasms | 3.5% |
| 387 | Ovulation Induction | 3.5% |
| 388 | Angioplasty | 3.5% |
| 389 | Blood culture | 3.5% |
| 390 | Immunoglobulin Therapy | 3.5% |
| 391 | Anus Neoplasms | 3.3% |
| 392 | Sigmoid Neoplasms | 3.3% |
| 393 | Paranasal Sinus Neoplasms | 3.2% |
| 394 | Maxillary Sinus Neoplasms | 3% |
| 395 | Leukapheresis | 2.7% |
| 396 | Atherectomy | 2.3% |
| 397 | Body mass index | 2.3% |
| 398 | PROTHROMBIN TIME | 2.1% |
| 399 | Glucose tolerance test | 2% |
| 400 | Superovulation | 2% |
| 401 | Clot retraction | 2% |
| 402 | Paracentesis | 1.8% |
| 403 | venipuncture | 1.7% |
| 404 | Body Height | 1.7% |
| 405 | Body Weight | 1.5% |
| 406 | Birth Weight | 1.2% |
| 407 | Fetal Weight | 0.9% |
